Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax
about
Anthrax vaccination strategiesImmunization of mice with formalin-inactivated spores from avirulent Bacillus cereus strains provides significant protection from challenge with Bacillus anthracis AmesNoninvasive imaging technologies reveal edema toxin as a key virulence factor in anthraxMolecular motions as a drug target: mechanistic simulations of anthrax toxin edema factor function led to the discovery of novel allosteric inhibitors.Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigenAnthrax prevention and treatment: utility of therapy combining antibiotic plus vaccine.Capsules, toxins and AtxA as virulence factors of emerging Bacillus cereus biovar anthracisThe Exosporium Layer of Bacterial Spores: a Connection to the Environment and the Infected HostCharacterization of a multi-component anthrax vaccine designed to target the initial stages of infection as well as toxaemia.Technical transformation of biodefense vaccines.Progress toward the Development of a NEAT Protein Vaccine for Anthrax Disease.Glycan surface antigens from Bacillus anthracis as vaccine targets: current status and future perspectives.Host immunity to Bacillus anthracis lethal factor and other immunogens: implications for vaccine design.Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model.Protection of farm goats by combinations of recombinant peptides and formalin inactivated spores from a lethal Bacillus anthracis challenge under field conditions.
P2860
Q28392248-919E7EC0-5D0D-4400-87E1-79DCEFCBC1E3Q28392659-54B26801-07ED-4072-872B-B73C9FCE2124Q30426565-777A60DA-CADF-412D-87C6-38ECFF7DD6E9Q30570720-7328E765-B649-4F50-80E5-146947C76E0AQ33496407-CE6D18FA-C92E-4035-80B7-BA556D2B698CQ33505445-32C5ED48-8094-4671-A406-9A430DFB4D6EQ35242802-08B3FB6A-25E1-4684-B7A2-7C2E69102EA3Q36294717-23F602BF-2804-4E9D-BDAB-284F09F38DC8Q36523135-7056699F-A949-4982-9BBC-E969848A6717Q37058898-3FAC97F2-5C20-47F5-9D33-C6D834E8DEC8Q37424982-666F28B5-BFBE-4B71-AAE5-F54667D0E0AEQ38215454-2204C9A5-A833-42F3-82B8-E7DB5C465056Q38268596-B73061DE-8281-4674-8BA0-951A41B0215CQ38760574-5C91A727-A0DA-428B-9792-852A2FDC514AQ39143157-86CAA68D-9B97-4E23-B667-33A56E4D27DB
P2860
Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Efficacy of a vaccine based on ...... erimental inhalational anthrax
@ast
Efficacy of a vaccine based on ...... erimental inhalational anthrax
@en
type
label
Efficacy of a vaccine based on ...... erimental inhalational anthrax
@ast
Efficacy of a vaccine based on ...... erimental inhalational anthrax
@en
prefLabel
Efficacy of a vaccine based on ...... erimental inhalational anthrax
@ast
Efficacy of a vaccine based on ...... erimental inhalational anthrax
@en
P2093
P2860
P356
P1476
Efficacy of a vaccine based on ...... erimental inhalational anthrax
@en
P2093
Dominique R Vidal
Jean-Charles Paucod
Jean-Nicolas Tournier
Jean-Philippe Corre
Michèle Mock
Pierre L Goossens
Yves P Gauthier
P2860
P304
P356
10.1128/IAI.01217-08
P407
P577
2008-12-29T00:00:00Z